23 / 154
349
REFERENCES
1. Louis DN, Perry A, Reifenberger G, et al: The 2016 World
Health Organization Classification of Tumors of the Central
Nervous System: a summary. Acta Neuropathol 131:803-20,
2016.
2. Yan H, Parsons DW, Jin G, et al: IDH1 and IDH2 mutations in
gliomas. N Engl J Med 360:765-73, 2009.
3. Buckner JC, Shaw EG, Pugh SL, et al: Radiation plus
Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N
Engl J Med 374:1344-55, 2016.
4. Van den Bent MJ: Interobserver variation of the
histopathological diagnosis in clinical trials on glioma: a
clinician’s perspective. Acta Neuropathol 120:297-304,
2010.
5. Giannini C, Scheithauer BW, Weaver AL, et al:
Oligodendrogliomas: reproducibility and prognostic value of
histologic diagnosis and grading. J Neuropathol Exp Neurol
60:248-62, 2001.
6. Louis DN, Ohgaki H, Wiestler OD, et al: The 2007 WHO
classification of tumours of the central nervous system. Acta
Neuropathol 114:97-109, 2007.
7. Broniscer A, Chamdine O, Hwang S, et al: Gliomatosis cerebri
in children shares molecular characteristics with other
pediatric gliomas. Acta Neuropathol 131:299-307, 2016.
8. Herrlinger U, Jones DT, Glas M, et al: Gliomatosis cerebri: no
evidence for a separate brain tumor entity. Acta Neuropathol
131:309-19, 2016.
9. Dang L, Yen K, Attar EC: IDH mutations in cancer and progress
toward development of targeted therapeutics. Ann Oncol
27:599-608, 2016.
10. Hartmann C, Meyer J, Balss J, et al: Type and frequency of
IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010
diffuse gliomas. Acta Neuropathol 118:469-74, 2009.
11. Turcan S, Rohle D, Goenka A, et al: IDH1 mutation is sufficient
to establish the glioma hypermethylator phenotype. Nature
483:479-83, 2012.
12. Figueroa ME, Abdel-Wahab O, Lu C, et al: Leukemic
IDH1 and IDH2 mutations result in a hypermethylation
phenotype, disrupt TET2 function, and impair hematopoietic
differentiation. Cancer Cell 18:553-67, 2010.
The authors declare no conflicts of interest, in relation to this article.
13. Van den Bent MJ, Dubbink HJ, Marie Y, et al: IDH1 and IDH2
mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European
Organization for Research and Treatment of Cancer Brain
Tumor Group. Clin Cancer Res 16:1597-604, 2010.
14. Wick W, Roth P, Hartmann C, et al: Long-term analysis
of the NOA-04 randomized phase III trial of sequential
radiochemotherapy of anaplastic glioma with PCV or
temozolomide. Neuro Oncol 18:1529-1537, 2016
15. Baumert BG, Hegi ME, van den Bent MJ, et al: Temozolomide
chemotherapy versus radiotherapy in high-risk low-grade
glioma (EORTC 22033-26033): a randomised, open-label,
phase 3 intergroup study. Lancet Oncol 17:1521-1532,
2016.
16. Seltzer MJ, Bennett BD, Joshi AD, et al: Inhibition of
glutaminase preferentially slows growth of glioma cells with
mutant IDH1. Cancer Res 70:8981-7, 2010.
17. Choi C, Raisanen JM, Ganji SK, et al: Prospective Longitudinal
Analysis of 2-Hydroxyglutarate Magnetic Resonance
Spectroscopy Identifies Broad Clinical Utility for the
Management of Patients With IDH-Mutant Glioma. Journal
of Clinical Oncology 34:4030-4039, 2016.
18. Andronesi OC, Rapalino O, Gerstner E, et al: Detection of
oncogenic IDH1 mutations using magnetic resonance
spectroscopy of 2-hydroxyglutarate. J Clin Invest 123:3659-
63, 2013.
19. Bertolino N, Marchionni C, Ghielmetti F, et al: Accuracy of
2-hydroxyglutarate quantification by short-echo proton-MRS
at 3 T: a phantom study. Phys Med 30:702-7, 2014.
20. Reifenberger J, Reifenberger G, Liu L, et al: Molecular genetic
analysis of oligodendroglial tumors shows preferential allelic
deletions on 19q and 1p. Am J Pathol 145:1175-90, 1994.
21. Labussiere M, Idbaih A, Wang XW, et al: All the 1p19q
codeleted gliomas are mutated on IDH1 or IDH2. Neurology
74:1886-90, 2010.
22. Cairncross JG, Ueki K, Zlatescu MC, et al: Specific genetic
predictors of chemotherapeutic response and survival in
patients with anaplastic oligodendrogliomas. J Natl Cancer
Inst 90:1473-9, 1998.
23. Cairncross G, Wang M, Shaw E, et al: Phase III trial of
CONCLUSION
Molecular markers are now incorporated as diagnostic and
prognostic indicators in the updated WHO 2016 classifica-
tion. Newer entities have been defined and some removed
in comparison to the WHO 2007 classification. Many markers
have increased our understanding of gliomagenesis and newer
targeted drugs showing promise in preclinical studies are
being evaluated in clinical trials. Challenges in clinical practice
and clinical trial designs are increasingly being recognized and
will need to be addressed with future studies.
[CLINICAL RELEVANCE OF MOLECULAR MARKERS IN GLIOMAS - Varun Monga, MBBS, et al]